Your browser doesn't support javascript.
loading
Mucopolisacaridosis: características clínicas, diagnóstico y de manejo / Mucopolysaccharidosis: clinical features, diagnosis and management
Suarez-Guerrero, Jorge Luis; Gómez Higuera, Pedro José Iván; Arias Flórez, Juan Sebastian; Contreras-García, Gustavo Adolfo.
  • Suarez-Guerrero, Jorge Luis; Universidad Industrial de Santander. Facultad de Salud. Bucaramanga. CO
  • Gómez Higuera, Pedro José Iván; Universidad Industrial de Santander. Facultad de Salud. Bucaramanga. CO
  • Arias Flórez, Juan Sebastian; Universidad Industrial de Santander. Facultad de Salud. Bucaramanga. CO
  • Contreras-García, Gustavo Adolfo; Universidad Industrial de Santander. Facultad de Salud. Bucaramanga. CO
Rev. chil. pediatr ; 87(4): 295-304, ago. 2016. ilus, tab
Article in Spanish | LILACS | ID: lil-796820
RESUMEN
Las mucopolisacaridosis (MPS) son un grupo de enfermedades raras (huérfanas), de baja prevalencia, caracterizadas por la deficiencia de enzimas que participan en el metabolismo de glucosaminglucanos (GAG) a nivel lisosomal. Se caracteriza por acumulación de GAG intracelular, produciendo alteraciones de múltiples órganos y sistemas. Su diagnóstico se basa en el conocimiento de las manifestaciones clínicas, realizar el análisis bioquímico para identificar el tipo de GAG que se está acumulando y confirmar el tipo de enfermedad con la determinación enzimática correspondiente. Su identificación es fundamental para iniciar un tratamiento oportuno, teniendo en cuenta que actualmente existe manejo transdisciplinario y tratamiento de reemplazo enzimático para MPS I (síndrome de Hurler), MPS II (síndrome de Hunter), MPS IV (síndrome de Morquio) y MPS VI (síndrome de Maroteaux-Lamy). En esta revisión se analizan cada uno de estos síndromes, su diagnóstico y tratamiento.
ABSTRACT
The mucopolysaccharidoses (MPS) are a group of rare (orphan) diseases, characterised by a deficiency of enzymes involved in the metabolism of glycosaminoglycans (GAGs) at lysosomal level. When there is a deficiency of a particular enzyme there is an accumulation of GAGs in the cells resulting in progressive cellular damage, which can affect multiple organ systems and lead to organ failure. Diagnosis is based on knowledge of the clinical manifestations, performing biochemical analyses to identify the type of GAG that is accumulating, and confirm the type of disorder with the corresponding enzymatic determination. Their identification is essential to initiate early treatment, taking into account that multidisciplinary management and enzyme replacement therapy is available for MPS I (Hurler syndrome), MPS II (Hunter syndrome), MPS IV (Morquio syndrome), and MPS VI (Maroteaux-Lamy syndrome. In this review, an analysis is made of each of these syndromes, as well as their diagnosis and treatment.
Subject(s)


Full text: Available Index: LILACS (Americas) Main subject: Mucopolysaccharidoses / Enzyme Replacement Therapy / Glycosaminoglycans Type of study: Diagnostic study / Prognostic study / Risk factors Limits: Animals / Humans Language: Spanish Journal: Rev. chil. pediatr Journal subject: Pediatrics Year: 2016 Type: Article Affiliation country: Colombia Institution/Affiliation country: Universidad Industrial de Santander/CO

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Index: LILACS (Americas) Main subject: Mucopolysaccharidoses / Enzyme Replacement Therapy / Glycosaminoglycans Type of study: Diagnostic study / Prognostic study / Risk factors Limits: Animals / Humans Language: Spanish Journal: Rev. chil. pediatr Journal subject: Pediatrics Year: 2016 Type: Article Affiliation country: Colombia Institution/Affiliation country: Universidad Industrial de Santander/CO